Philip J. Vickers - May 4, 2022 Form 4/A - restatement Insider Report for Revance Therapeutics, Inc. (RVNC)

Role: Director
Signature: /s/ Dwight Moxie, Attorney-in-Fact
Stock symbol: RVNC
Transactions as of: May 4, 2022
Transactions value $: $0
Form type: 4/A - RESTATEMENT
Date filed: 5/13/2022, 06:13 PM
Date Of Original Report: May 6, 2022
Previous filing: Jul 8, 2021
Next filing: Jun 10, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RVNC	Stock Option (Right to buy)	Award	$0	+10.8 K		$0.00	10.8 K	May 4, 2022	Common Stock	10.8 K	$18.12	Direct	F1

Explanation of Responses:

Id	Content
F1	The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Dr. Vickers' Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) through such vesting date. The stock option represents an annual grant pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy.

Remarks:

The original Form 4, filed on May 6, 2022, inadvertently listed the incorrect number of options granted to the Reporting Person on May 4, 2022 due to an administrative error. This Form 4/A is being filed to correct the number of shares underlying the stock option originally reported.